Scholars Central

Conference abstractPublished 24 Jan 2020

Receptor binding of a novel bifunctional TGF-andbeta;1/PD-L1 fusion protein elicited a downregulated immune signature

Authors: Marvin I De los Santos

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: There are more than 80 clinical distinct types of autoimmune diseases (AID) and their collective global prevalence rate have increased to >10%. Until now, treatment regimen has relied heavily on the use of drugs (i.e. NSAIDs, glucocorticoids and DMARDs) that down-regulate the entire body’s immune response. High-dose and long-term medication with these drugs have been found to correlate with susceptibility to infections and tumorigenesis. Preclinical studies targeting the receptors of transforming growth factor superfamily such as TGF-β1 has implicated possible use of this molecule in AID management and treatment. However, researchers have reported several drawbacks of targeting TGF-β1 signaling, as they found its involvement in prevention but not reversal of AID. Another group of immune checkpoint protein, the PD-1/PD-L1 axis, has been found to down-regulate immune response and have clinical implications for treatment of the disease. This study aims to utilize the combinatorial immunedownregulating activities of TGF-β1 and PD-L1 by generating a fusion product which has never been described before. Methodology: We were able to previously successfully clone and generate a fusion gene construct of TGF-β1 and PD-L, validated by DNA sequencing. The study focused next on characterizing the bifunctional binding of the proteins with their respective receptors by co-immunoprecipitation (co-IP) and reverse co-IP experiments coupled with pathway analysis by qRT-PCR. Findings and Results: A 70 kDa TGF-β1/PD-L1 fusion protein was demonstrated to bind TGF-β1 receptors such as TGF-β receptor 1 and PD-L1 target receptor, PD-1, in co-IP and reverse co-IP experiments. Gene expression analysis showed that these interactions are functional and elicit gene expression signature that is seen in suppressed immunity using a cell line model. Conclusion and Significance: TGF-β1/PD-L1 fusion protein may represent a new class of immunotherapy for treatment and management of autoimmune diseases in the future.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cancer & Metastasis Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cancer & Metastasis Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Marvin I De los Santos”